Nafazatrom is a pyrazolinone derivative and lipoxygenase inhibitor that increases endogenous prostacyclin (PGI2) and has experimental anticancer activity. Nafazatrom is also an antithrombotic drug that increases prostacyclin levels and reduces the incidence of arrhythmias associated with cardiac injury.

59040-30-1

C16H16N2O2

268.31

Nafazatromum;Nafazatrom

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years